SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)

Also known as: AZD1222 ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca

Therapeutic indications

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for:

Active immunisation to prevent COVID-19 caused by SARS-CoV-2

Population group: both men and women, only adults (18 years old or older)

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner
< Previous: Overview
Next: Precautions >